Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Sirius Therapeutics announced that the first patient has been dosed in a Phase II clinical trial...
Sirius Therapeutics
Sirius Therapeutics’ SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases
China-based Sirius Therapeutics announced on July 23, 2025, that its next-generation siRNA therapy, SRSD107, has...
Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis
Sino-US biotech Sirius Therapeutics has entered into a partnership with Swiss–American biotech CRISPR Therapeutics (NASDAQ:...
Sirius Therapeutics Pursues First-in-Human Trial for SRSD107 in Australia
Sino-US biotech Sirius Therapeutics has announced its pursuit of Investigational New Drug (IND) approval in...
Sirius Therapeutics Secures USD 60 Million in Series B Financing for siRNA Therapy Development
Sirius Therapeutics, a Shanghai-based developer of siRNA therapies, has successfully raised USD 60 million in...